welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, and Marina Biotech, Inc., a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced that the companies have executed a term sheet under which Microlin intends to acquire Marina’s nucleic acid therapeutics assets.
expertly curated content related to this topic
- Dee HenschelDee Henschel is a FAP previvor, proud mo...
- José G. Guillem, MDDr. José G. Guillem is a colorectal sur...
- Amie M. Blanco, MS, CGCEducation:Undergraduate studies at t...
- Texas Children’s HospitalTexas Children's Hospital, located in Ho...
- Patrick M. Lynch, JD, MDDr. Patrick Lynch grew up in a Lynch s...
- Steven M. Lipkin, MD, PhDDr. Lipkin is a board certified Clinical...
- MD Anderson Cancer CenterClinical Trial CenterPatient Resourc...
English
Portuguese
Spanish